Journal of Pharmacy Technology最新文献

{"title":"Tricyclic Antidepressants in Nociceptive and Neuropathic Pain: A Review of Their Analgesic Properties in Combination With Opioids.","authors":"Justin P Reinert, Michael A Veronin, Christopher Medina","doi":"10.1177/87551225221139699","DOIUrl":"10.1177/87551225221139699","url":null,"abstract":"<p><p><b>Objectives:</b> To determine the efficacy and safety of commonly prescribed tricyclic antidepressants (TCAs) as analgesics for nociceptive and neuropathic pain in combination with opioids. <b>Data Sources:</b> A comprehensive literature review was conducted with the assistance of a medical reference librarian on PubMed, MEDLINE, Scopus, and Web of Science using the following search terminology: \"Amitriptyline\" OR \"Doxepin\" OR \"Desipramine\" OR \"Imipramine\" OR \"Nortriptyline\" OR \"Clomipramine\" OR \"Trimipramine\" AND \"Analgesia.\" Reports of adult patients who received any TCA as an adjunctive analgesic to opioids were included. <b>Study Selection and Data Extraction:</b> A total of 293 results were obtained from the initial database inquiries, following which exclusion criteria were applied and 6 articles were included in this review. Three of the reports detailed the use of TCAs in the perioperative setting, whereas the remaining 3 evaluated their effect on different etiologies of neuropathic pain. <b>Data Synthesis:</b> Tricyclic antidepressants were found to have modest, yet not insignificant, independent analgesic properties, although the ability to provide pain relief was relegated to a select few agents. Desipramine has the most data available for use in nociceptive, postoperative pain through its ability to potentiate and prolong the analgesic effects of opioids and was not associated with adverse drug effects. <b>Conclusions:</b> The efficacy of TCAs for neuropathic pain was not corroborated by this review, and the anticholinergic adverse effects associated with this drug class were found to be significant. Further research is needed to quantify the efficacy of TCAs in the management of nociceptive pain.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10684333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Weight Loss With Semaglutide in Elderly Patients With Type II Diabetes.","authors":"Grace Huynh, Haley Runeberg, Rick Weideman","doi":"10.1177/87551225221137493","DOIUrl":"10.1177/87551225221137493","url":null,"abstract":"<p><p><b>Background:</b> Semaglutide is an effective agent indicated for type II diabetes mellitus (T2DM) treatment and weight management. It is unknown if the magnitude of weight loss differs significantly between nonelderly (18-64 years old) and elderly (≥65 years old) patients diagnosed with T2DM. <b>Objective:</b> To determine whether there is a significant difference in percent weight loss between elderly and nonelderly Veterans diagnosed with T2DM and initiating semaglutide. <b>Methods:</b> This institutional review board-approved retrospective cohort study conducted at the VA North Texas Health Care System included adult Veterans with T2DM initiating semaglutide. Veterans with medications, procedures, or conditions that could significantly affect weight were excluded. The primary endpoint was the difference in percent weight loss 3 months after initiating semaglutide. Secondary endpoints were differences in percent weight loss at 6 months and differences of kilogram weight loss at 3 and 6 months. Safety outcomes were significant adverse drug events (ADEs) associated with semaglutide. <b>Results:</b> In total, 177 Veterans were analyzed (n = 111 elderly, n = 66 nonelderly). For the primary endpoint, elderly Veterans lost a mean of 2.02% body weight versus 2.25% in the nonelderly with a mean difference of 0.23% (95% CI, -1.03% to 1.48%; <i>P</i> = 0.72). Secondary endpoints were also not statistically significant. Significant ADEs were gastrointestinal-related, leading to drug discontinuation or dose reduction. <b>Conclusion:</b> Weight loss differences between elderly and nonelderly Veterans diagnosed with T2DM initiating semaglutide were not statistically significant. Age may not be a robust predictor of semaglutide's influence on weight.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10684334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hello Operator? A Pharmacy Practice Simulation to Increase Student Confidence in Telephone Communication Skills.","authors":"Tori A Rude, Michael P Kelsch, Mikayla Fingarson, Heidi N Eukel","doi":"10.1177/87551225221135794","DOIUrl":"10.1177/87551225221135794","url":null,"abstract":"Background: Communicating interprofessionally using the telephone is an essential skill within pharmacy practice. Student pharmacists’ ability to perform this task effectively and efficiently may be hindered by generational changes, social anxiety, and very few opportunities to practice these skills. Objective: The purpose of this study was to develop and implement a simulation allowing students to practice interprofessional communication and assess the simulation’s impact on students’ confidence in providing pharmacy-related interventions to another health care professional via telephone. Methods: Faculty developed a simulation focused on interprofessional telephone communication. Baseline student information was collected to quantify pharmacy work experience in terms of practice setting, duration of employment, and skills. Presimulation and postsimulation surveys evaluated self-assessed telephone-related skills, attitudes, and confidence. Quantitative data were analyzed with descriptive statistics. Qualitative data were evaluated through a thematic analysis of students’ reflective responses to 2 open-ended questions. Results: Of the 53 pharmacy students that participated in the simulation, 44 (83%) and 43 (81%) completed the anonymous presimulation and postsimulation surveys. Students significantly improved as reflected in the following response: “I have confidence in my ability to provide pharmacy-related interventions to another health care professional in a logical and concise manner via telephone call.” Significant improvement also occurred in the ability to work independently, communicate an order change to another health care professional, justify recommendations, answer a drug information question, and discuss recommendations in a logical and concise manner. Conclusion: The simulation discussed in this article provided students an opportunity to practice interprofessional telephone communication in a low-risk environment and resulted in significant growth in confidence and skills.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9252338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Azathioprine-Induced Acute Pancreatitis in a Patient With Inflammatory Bowel Disease.","authors":"Silvia Vázquez-Gómez,&nbsp;Lorena Vázquez-Gómez","doi":"10.1177/87551225221126353","DOIUrl":"10.1177/87551225221126353","url":null,"abstract":"Patients with inflammatory bowel disease (IBD) show a higher risk of developing pancreatitis, the main cause being side effects due to medication. Azathioprine (AZA) is a thiopurine immunosuppressant drug indicated for the treatment of this pathology and is one of the active ingredients most associated with acute pancreatitis in those patients.1 According to Gordon et al,2 the effect size and morbidity of thiopurine-induced pancreatitis are not known. Studies in adults report an incidence of AZA-induced pancreatitis ranging from 0% to 11%, depending on the type of study (observational vs randomized trial). Small case series report an incidence of up to 6% in pediatric IBD; however, only few prospective controlled studies with a comparison group have been published. Therefore, the absolute and relative risks of AZA-induced acute pancreatitis in children with IBD are unknown yet.3 We report a case of a pediatric patient who probably had AZA-induced pancreatitis. An 11-years-old boy, diagnosed with Crohn’s disease (CD) in June 2021, with neither known drug allergies nor other history of interest, was admitted for suffering from epigastric pain of days of evolution, accompanied by nausea and vomiting. He received treatment with exclusive enteral nutrition and oral AZA (50 mg daily), based on determination of thiopurine methyltransferase (TPMT) activity (17.6 U/mL), started 3 weeks before admission. The abdominal pain was continuous with exacerbations, predominantly at night, and no changes in bowel habits (type 4-6 according to the Bristol Stool Scale) were observed. Physical examination revealed a non-distended, but painful abdomen in the supraumbilical region, with no other findings of interest. A blood test showed normal blood and coagulation parameters, amylase value being 70 UI/L. Abdominal ultrasonography showed subcentimeter adenopathies in the flank and right iliac fossa. During admission, he was maintained on an absolute diet with intravenous fluid therapy (antiemetics—ondansetron—and gastric protection—ranitidine), without clinical improvement. Due to the persistence of the symptoms, successive analytical controls were requested. Finally, elevation of amylase to 174 UI/L and pancreatic lipase to 397 UI/L were objectifying (Figure 1). Because drug-induced pancreatitis usually develops after 2-3 weeks from starting medication,4-6 AZA was considered the possible cause of the pancreatitis. Therefore, AZA was discontinued. A decrease in serum pancreatic enzyme values was observed (Figure 1), and abdominal pain disappeared after withdrawal of AZA. After confirming the diagnosis, clinical course of the patient improved in a short time. 1126353 PMTXXX10.1177/87551225221126353Journal of Pharmacy TechnologyVázquez-Gómez and Vázquez-Gómez research-article2022","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899964/pdf/10.1177_87551225221126353.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9252340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Risk of Cardiac or Cerebrovascular Events in Romosozumab Users Focusing on Comorbidities: Analysis of the Japanese Adverse Drug Event Report Database.","authors":"Kazumasa Kotake, Satoru Mitsuboshi, Yuki Omori, Yukio Kawakami, Yasuhiro Kawakami","doi":"10.1177/87551225221144960","DOIUrl":"10.1177/87551225221144960","url":null,"abstract":"<p><p><b>Background:</b> Romosozumab is associated with an increased risk of cardiac or cerebrovascular events. Identifying the risk factors for these events could contribute to the safe use of romosozumab. <b>Objective:</b> This study aimed to investigate risk factors for cardiac or cerebrovascular events in romosozumab users. <b>Methods:</b> First, disproportionality analysis was performed to compare the frequency of cardiac or cerebrovascular events, using data from the Japanese Adverse Drug Event Report database. Next, multivariate logistic analysis was performed to investigate risk factors for cardiac or cerebrovascular events in romosozumab users. <b>Results:</b> In total, 859 romosozumab users were identified. A disproportionality of both cardiac and cerebrovascular events was observed in only romosozumab users. Multivariate logistic analysis revealed that the risk of cardiac events in romosozumab users was significantly increased in patients with cardiac disease (odds ratio [OR]: 5.9, 95% confidence interval [CI] 3.5-9.9; <i>P</i> < 0.01) and hypertension (OR: 1.6, 95% CI 1.0-2.7; <i>P</i> = 0.047). In addition, the risk of cerebrovascular events in romosozumab users was significantly increased in the presence of cerebrovascular disease (OR: 2.7, 95% CI 1.2-6.2; <i>P</i> = 0.02) and hypertension (OR: 2.6, 95% CI 1.7-3.9; <i>P</i> < 0.01). <b>Conclusion:</b> Our findings suggest that hypertension may increase the risk of cardiac or cerebrovascular events in romosozumab users. Although additional studies are needed to assess other associated factors, these findings may contribute to the appropriate use of romosozumab and limit adverse events.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9237321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reviewer Acknowledgment.","authors":"","doi":"10.1177/87551225221144153","DOIUrl":"https://doi.org/10.1177/87551225221144153","url":null,"abstract":"","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9244029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Longitudinal Comparison of Pharmacy Documentation Platforms Using the Technology Acceptance Model: Experiences With Opioid Risk Screening.","authors":"Oliver C Frenzel,&nbsp;Mark Strand,&nbsp;Allison Welsh,&nbsp;Heidi Eukel,&nbsp;Elizabeth Skoy,&nbsp;Jayme Steig,&nbsp;Amy Werremeyer","doi":"10.1177/87551225221128207","DOIUrl":"10.1177/87551225221128207","url":null,"abstract":"<p><p><b>Background:</b> Pharmacy practice continues to expand in scope, and technology platforms to assist with meeting the standards for documentation of billable services are needed. The ONE Program (Opioid and Naloxone Education) is an initiative centered on the community pharmacy focused on opioid risk screening for patients receiving opioid prescriptions. <b>Objective:</b> Opioid risk screening results and pharmacist interventions were documented using first REDCap and later the DocStation platforms. This study compared pharmacy staff experience with these 2 platforms. <b>Methods:</b> A survey using the Technology Acceptance Model (TAM) was designed to compare usability, ease of use, social influence, and facilitating conditions. <b>Results:</b> Analyses using descriptive statistics and open-ended responses showed similar results for each platform; however, pharmacy staff indicated that REDCap required less time when entering information, whereas the DocStation platform offered elevated pharmacy practice service opportunities, management support, and available informational technology support services. <b>Conclusion:</b> Health care technology continues to advance in meeting the needs of expanded service provision through pharmacy. This longitudinal study shows the value of the TAM framework in identifying efficiencies and deficiencies of health care technology systems.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899959/pdf/10.1177_87551225221128207.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9252342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quick Response Codes: A Tool to Improve Access for Patients With Limited English Proficiency.","authors":"Jason Fine,&nbsp;Julie MacDougall","doi":"10.1177/87551225221128204","DOIUrl":"10.1177/87551225221128204","url":null,"abstract":"","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899960/pdf/10.1177_87551225221128204.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10684335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists' Perceptions About the Effect of Work Environment Factors on Patient Safety in Large-Chain Retail Pharmacies.","authors":"Sarah G Francis","doi":"10.1177/87551225221116000","DOIUrl":"https://doi.org/10.1177/87551225221116000","url":null,"abstract":"<p><p>This commentary evaluates large-chain retail pharmacists' perceptions on their work environment factors' effects on patient safety from the July 2020 survey conducted by the Ohio Board of Pharmacy. Respondents rated 7 questions using a 5-point Likert scale to rate how they perceive work environment factors in large-chain retail pharmacies influence patient safety. Weighted average, weighted sums, and weighted total scores were calculated to determine if pharmacists' perceptions were positive or negative. Low scores indicated pharmacists' negative perceptions. Work factors in large-chain retail pharmacies need to change to improve pharmacists' perception about work environment factors on patient safety.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608101/pdf/10.1177_87551225221116000.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10410441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension.","authors":"Shraddha Narechania,&nbsp;Mark A Malesker","doi":"10.1177/87551225221114001","DOIUrl":"https://doi.org/10.1177/87551225221114001","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the potential for drug interactions with therapies for pulmonary arterial hypertension (PAH). Treatments include calcium channel blockers, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin receptor agonists. <b>Data Sources:</b> A systemic literature search (January 1980-December 2021) was performed using PubMed and EBSCO to locate relevant articles. The mesh terms used included each specific medication available as well as \"drug interactions.\" DAILYMED was used for product-specific drug interactions. <b>Study Selection and Data Extraction:</b> The search was conducted to identify drug interactions with PAH treatments. The search was limited to those articles studying human applications with PAH treatments and publications using the English language. Case reports, clinical trials, review articles, treatment guidelines, and package labeling were selected for inclusion. <b>Data Synthesis:</b> Primary literature and package labeling indicate that PAH treatments are subject to pharmacokinetic and pharmacodynamic interactions. The management of PAH is rapidly evolving. As more and more evidence becomes available for the use of combination therapy in PAH, the increasing use of combination therapy increases the risk of drug-drug interactions. Pulmonary arterial hypertension is also associated with other comorbidities that require concomitant pharmacotherapy. <b>Conclusion:</b> The available literature indicates that PAH therapies are associated with clinically significant drug interactions and the potential for subsequent adverse reactions. Clinicians in all practice settings should be mindful that increased awareness of drug interactions with PAH therapy will ensure optimal management and patient safety.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608103/pdf/10.1177_87551225221114001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9946909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}